Eva María Satué Gracia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eva María Satué Gracia has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Angel Vila-Corcoles
Primary Health Care Service "Camp de Tarragona", Institut Catala de la Salut, Tarragona, Spain
11 shared publications - Olga Ochoa-Gondar
Primary Care Department Camp de Tarragona. Institut Catala de la Salut, Tarragona, Spain
10 shared publications - Francisco Martín-Luján
Primary Healthcare Research Support Unit Camp de Tarragona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Reus, Spain
8 shared publications Olga Ochoa-Gondar
Primary Health Care Service "Camp de Tarragona", Institut Catala de la Salut, Tarragona, Spain
6 shared publicationsAngel Vila-Rovira
Primary Health Care Service "Camp de Tarragona", Institut Catala de la Salut, Tarragona, Spain
4 shared publicationsCinta de Diego
A Primary Health Care Service "Camp de Tarragona," Institut Català de la Salut , Tarragona , Spain
4 shared publications
Latest Publications
- Open Access
- 7 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 119
Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)
Background/Objectives: In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3–5 individuals after the age of 55 years and a 34% rise in AF-related strokes. The PREFATE project investigates evidence gaps in the early detection of atrial fibrillation in high-risk populations within primary care. This study aims to estimate the prevalence of device-detected atrial fibrillation (DDAF) and assess the feasibility and impact of systematic screening in routine primary care. Methods: The prospective cohort study (NCT 05772806) included 149 patients aged 65–85 years, identified as high-risk for AF. Participants underwent 14 days of cardiac rhythm monitoring using the Fibricheck® app (CE certificate number BE16/819942412), alongside evaluations with standard ECG and transthoracic echocardiography. The primary endpoint was a new AF diagnosis confirmed by ECG or Holter monitoring. Statistical analyses examined relationships between AF and clinical, echocardiographic, and biomarker variables. Results: A total of 18 cases (12.08%) were identified as positive for possible DDAF using FibriCheck® and 13 new cases of AF were diagnosed during follow-up, with a 71.4-fold higher probability of confirming AF in FibriCheck®-positive individuals than in FibriCheck®-negative individuals, resulting in a post-test odds of 87.7%. Significant echocardiographic markers of AF included reduced left atrial strain (<26%) and left atrial ejection fraction (<50%). MVP ECG risk scores ≥ 4 strongly predicted new AF diagnoses. However, inconsistencies in monitoring outcomes and limitations in current guidelines, particularly regarding AF burden, were observed. Conclusions: The study underscores the feasibility and utility of AF screening in primary care but identifies critical gaps in diagnostic criteria, anticoagulation thresholds, and guideline recommendations.
- 7 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 119
Open AccessEvidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)
Background/Objectives: In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3–5 individuals after the age of 55 years and a 34% rise in AF-related strokes. The PREFATE project investigates evidence gaps in the early detection of atrial fibrillation in high-risk populations within primary care. This study aims to estimate the prevalence of device-detected atrial fibrillation (DDAF) and assess the feasibility and impact of systematic screening in routine primary care. Methods: The prospective cohort study (NCT 05772806) included 149 patients aged 65–85 years, identified as high-risk for AF. Participants underwent 14 days of cardiac rhythm monitoring using the Fibricheck® app (CE certificate number BE16/819942412), alongside evaluations with standard ECG and transthoracic echocardiography. The primary endpoint was a new AF diagnosis confirmed by ECG or Holter monitoring. Statistical analyses examined relationships between AF and clinical, echocardiographic, and biomarker variables. Results: A total of 18 cases (12.08%) were identified as positive for possible DDAF using FibriCheck® and 13 new cases of AF were diagnosed during follow-up, with a 71.4-fold higher probability of confirming AF in FibriCheck®-positive individuals than in FibriCheck®-negative individuals, resulting in a post-test odds of 87.7%. Significant echocardiographic markers of AF included reduced left atrial strain (<26%) and left atrial ejection fraction (<50%). MVP ECG risk scores ≥ 4 strongly predicted new AF diagnoses. However, inconsistencies in monitoring outcomes and limitations in current guidelines, particularly regarding AF burden, were observed. Conclusions: The study underscores the feasibility and utility of AF screening in primary care but identifies critical gaps in diagnostic criteria, anticoagulation thresholds, and guideline recommendations.
- Open Access
- 17 December 2024
- Published by MDPI AG in Preprints.org
Evidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)
Background/Objectives: In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3-5 individuals after the age of 55 years and a 34% rise in AF-related strokes. The PREFATE project investigates evidence gaps in the early detection of atrial fibrillation in high-risk populations within primary care. This study aims to estimate the prevalence of device-detected atrial fibrillation (DDAF) and assess the feasibility and impact of systematic screening in routine primary care. Methods: prospective cohort study (NCT 05772806) included 149 patients aged 65–85 years, identified as high-risk for AF. Participants underwent 14 days of cardiac rhythm monitoring using the Fibricheck® app, alongside evaluations with standard ECG and transthoracic echocardiography. The primary endpoint was a new AF diagnosis confirmed by ECG or Holter monitoring. Statistical analyses examined relationships between AF and clinical, echocardiographic, and biomarker variables. Results: A total of 18 cases (12.08%) were identified as positive for possible DDAF using FibriCheck® and 13 new cases of AF were diagnosed during follow-up, with a 71.4-fold higher probability of confirming AF in FibriCheck®-positive individuals than in FibriCheck®-negative individuals, resulting in a post-test odds of 87.7%. Significant echocardiographic markers of AF included reduced left atrial strain (<26%) and left atrial ejection fraction (<50%). MVP ECG risk scores ≥4 strongly predicted new AF diagnoses. However, inconsistencies in monitoring outcomes and limitations in current guidelines, particularly regarding AF burden, were observed. Conclusions: The study underscores the feasibility and utility of AF screening in primary care but identifies critical gaps in diagnostic criteria, anticoagulation thresholds, and guideline recommendations.
- 17 December 2024
- Published by MDPI AG in Preprints.org
Open AccessEvidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)
Background/Objectives: In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3-5 individuals after the age of 55 years and a 34% rise in AF-related strokes. The PREFATE project investigates evidence gaps in the early detection of atrial fibrillation in high-risk populations within primary care. This study aims to estimate the prevalence of device-detected atrial fibrillation (DDAF) and assess the feasibility and impact of systematic screening in routine primary care. Methods: prospective cohort study (NCT 05772806) included 149 patients aged 65–85 years, identified as high-risk for AF. Participants underwent 14 days of cardiac rhythm monitoring using the Fibricheck® app, alongside evaluations with standard ECG and transthoracic echocardiography. The primary endpoint was a new AF diagnosis confirmed by ECG or Holter monitoring. Statistical analyses examined relationships between AF and clinical, echocardiographic, and biomarker variables. Results: A total of 18 cases (12.08%) were identified as positive for possible DDAF using FibriCheck® and 13 new cases of AF were diagnosed during follow-up, with a 71.4-fold higher probability of confirming AF in FibriCheck®-positive individuals than in FibriCheck®-negative individuals, resulting in a post-test odds of 87.7%. Significant echocardiographic markers of AF included reduced left atrial strain (<26%) and left atrial ejection fraction (<50%). MVP ECG risk scores ≥4 strongly predicted new AF diagnoses. However, inconsistencies in monitoring outcomes and limitations in current guidelines, particularly regarding AF burden, were observed. Conclusions: The study underscores the feasibility and utility of AF screening in primary care but identifies critical gaps in diagnostic criteria, anticoagulation thresholds, and guideline recommendations.
- 16 December 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (6) , 1455-1464
Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in Adults: A Population-Based Study
Background: Information concerning sex differences in pneumococcal vaccine effectiveness in adults is scarce. The main aim of this study is to compare the differences in clinical effectiveness of pneumococcal vaccination between male and female. Methods: This was a population-based cohort study involving 1 108 634 women and 951 011 men aged ≥50 years in Catalonia, Spain. Baseline characteristics of cohort members were established according to Institutional Research Database and pneumococcal disease-related hospitalizations (PDRH) captured from hospital discharge codes from 68 reference Catalonian hospitals during 2017–2018. Cox regression models were used to estimate PPsV23/PCV13 effectiveness against PDRH by sex. Results: Across the 2-year follow-up, 4302 PDRH cases (1878 women, 2424 men) were observed, with incidences of 169.4/100 000 and 254.9/100 000 for women and men, respectively. Among women, neither PPsV23 (hazard ratio [HR], 1.04; 95% confidence interval [CI], .92–1.18; P = .540) or PCV13 (HR, 1.24; 95% CI, .91–1.70; P = .171) altered PDRH risk. Among men, PCV13 was associated with significantly increased risk of PDRH (HR, 1.57; 95% CI, 1.07–2.31; P = .021) whereas PPsV23 did not significantly alter this risk (HR, 0.89; 95% CI, .72–1.10; P = .275). No reduced risk of death following PDRH was observed in vaccinated women or men. However, regarding all-cause death, PPsV23 showed slight reduction in risk for women (HR, 0.94; 95% CI, .92–.97; P < .001). Conclusions: PPsV23/PCV13 vaccinations have not proven effective for either sex in preventing PDRH. PPsV23 appears associated with slight reduction risk of all-cause death in women, which could be related to better or longer-lasting vaccination effects in women compared to men.
- 16 December 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (6) , 1455-1464
Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in Adults: A Population-Based Study
Background: Information concerning sex differences in pneumococcal vaccine effectiveness in adults is scarce. The main aim of this study is to compare the differences in clinical effectiveness of pneumococcal vaccination between male and female. Methods: This was a population-based cohort study involving 1 108 634 women and 951 011 men aged ≥50 years in Catalonia, Spain. Baseline characteristics of cohort members were established according to Institutional Research Database and pneumococcal disease-related hospitalizations (PDRH) captured from hospital discharge codes from 68 reference Catalonian hospitals during 2017–2018. Cox regression models were used to estimate PPsV23/PCV13 effectiveness against PDRH by sex. Results: Across the 2-year follow-up, 4302 PDRH cases (1878 women, 2424 men) were observed, with incidences of 169.4/100 000 and 254.9/100 000 for women and men, respectively. Among women, neither PPsV23 (hazard ratio [HR], 1.04; 95% confidence interval [CI], .92–1.18; P = .540) or PCV13 (HR, 1.24; 95% CI, .91–1.70; P = .171) altered PDRH risk. Among men, PCV13 was associated with significantly increased risk of PDRH (HR, 1.57; 95% CI, 1.07–2.31; P = .021) whereas PPsV23 did not significantly alter this risk (HR, 0.89; 95% CI, .72–1.10; P = .275). No reduced risk of death following PDRH was observed in vaccinated women or men. However, regarding all-cause death, PPsV23 showed slight reduction in risk for women (HR, 0.94; 95% CI, .92–.97; P < .001). Conclusions: PPsV23/PCV13 vaccinations have not proven effective for either sex in preventing PDRH. PPsV23 appears associated with slight reduction risk of all-cause death in women, which could be related to better or longer-lasting vaccination effects in women compared to men.
- Open Access
Protocol for a multicentre and prospective follow-up cohort study of early detection of atrial fibrillation, silent stroke and cognitive impairment in high-risk primary care patients: the PREFA-TE study
Background: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. Future estimations suggest an increase in global burden of AF greater than 60% by 2050. Numerous studies provide growing evidence that AF is not only associated with stroke but also with cognitive impairment and dementia. Aim: The main goal is to assess the impact of the combined use of cardiac rhythm monitoring devices, echocardiography, biomarkers and neuroimaging on the early diagnosis of AF, silent strokes and cognitive decline, in subjects at high risk of AF. Methods and analysis: Two-year follow-up of a cohort of individuals aged 65–85 years at high risk for AF, with no prior diagnosis of either stroke or dementia. The study involves baseline echocardiography, biomarkers, and neuroimaging, yearly cardiac monitoring, and semiannual clinical assessments. Different parameters from these tests will be analysed as independent variables. Throughout the study period, primary outcomes: new diagnoses of AF, stroke and cognitive impairment, along with any clinical and therapeutic changes, will be registered. A first descriptive and bivariate statistical analysis, appropriate to the types of variables, will be done. The information obtained from the data analysis will encompass adjusted risk estimates along with 95% confidence intervals. Event risk predictions will rely on multivariate Cox proportional hazards regression models. The predictive value of the model will be evaluated through the utilisation of receiver operating characteristic curves for area under the curve calculation. Additionally, time-to-event analysis will be performed using Kaplan-Meier curves. Ethics and dissemination: This study protocol has been reviewed and approved by the Independent Ethics Committee of the Foundation University Institute for Primary Health Care Research-IDIAP Jordi Gol (expedient file 22/090-P). The authors plan to disseminate the study results to the general public through various scientific events. Publication in open-access journals and presentations at scientific congresses, seminars and meetings is also foreseen. Trial registration number: NCT05772806 .
Open AccessProtocol for a multicentre and prospective follow-up cohort study of early detection of atrial fibrillation, silent stroke and cognitive impairment in high-risk primary care patients: the PREFA-TE study
Background: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. Future estimations suggest an increase in global burden of AF greater than 60% by 2050. Numerous studies provide growing evidence that AF is not only associated with stroke but also with cognitive impairment and dementia. Aim: The main goal is to assess the impact of the combined use of cardiac rhythm monitoring devices, echocardiography, biomarkers and neuroimaging on the early diagnosis of AF, silent strokes and cognitive decline, in subjects at high risk of AF. Methods and analysis: Two-year follow-up of a cohort of individuals aged 65–85 years at high risk for AF, with no prior diagnosis of either stroke or dementia. The study involves baseline echocardiography, biomarkers, and neuroimaging, yearly cardiac monitoring, and semiannual clinical assessments. Different parameters from these tests will be analysed as independent variables. Throughout the study period, primary outcomes: new diagnoses of AF, stroke and cognitive impairment, along with any clinical and therapeutic changes, will be registered. A first descriptive and bivariate statistical analysis, appropriate to the types of variables, will be done. The information obtained from the data analysis will encompass adjusted risk estimates along with 95% confidence intervals. Event risk predictions will rely on multivariate Cox proportional hazards regression models. The predictive value of the model will be evaluated through the utilisation of receiver operating characteristic curves for area under the curve calculation. Additionally, time-to-event analysis will be performed using Kaplan-Meier curves. Ethics and dissemination: This study protocol has been reviewed and approved by the Independent Ethics Committee of the Foundation University Institute for Primary Health Care Research-IDIAP Jordi Gol (expedient file 22/090-P). The authors plan to disseminate the study results to the general public through various scientific events. Publication in open-access journals and presentations at scientific congresses, seminars and meetings is also foreseen. Trial registration number: NCT05772806 .
- Open Access
- 22 December 2023
- Published by MDPI AG in Diagnostics
- Vol. 14 (1) , 29
Validity of the Espiro Mobile Application in the Interpretation of Spirometric Patterns: An App Accuracy Study
Spirometry is a pulmonary function test where correct interpretation of the results is crucial for accurate diagnosis of disease. There are online tools to assist in the interpretation of spirometry results; however, as yet none are validated. We evaluated the interpretation accuracy of the Espiro app using pulmonologist interpretations as the gold standard. This is an observational descriptive study in which 118 spirometry results were interpreted by the Espiro app, two pulmonologists, two primary care physicians, and two residents of a primary care training program. We determined the interpretation accuracy of the Espiro app and the concordance of the pattern and severity interpretation between the Espiro app and each of the observers using Cohen’s kappa coefficient (k). We obtained a sensitivity and specificity for the Espiro app of 97.5% (95% confidence interval (CI): 86.8–99.9%) and 94.9% (95%CI: 87.4–98.6%) with pulmonologist 1 and 100% (95%CI: 91.6–100%) and 98.7% (95%CI: 92.9–99.9%) with pulmonologist 2. The concordance for the pattern interpretation was greater than k 0.907, representing almost perfect agreement. The concordance of the severity interpretation was greater than k 0.807, representing substantial to almost perfect agreement. We concluded that the Espiro app is a valid tool for spirometry interpretation.
- 22 December 2023
- Published by MDPI AG in Diagnostics
- Vol. 14 (1) , 29
Open AccessValidity of the Espiro Mobile Application in the Interpretation of Spirometric Patterns: An App Accuracy Study
Spirometry is a pulmonary function test where correct interpretation of the results is crucial for accurate diagnosis of disease. There are online tools to assist in the interpretation of spirometry results; however, as yet none are validated. We evaluated the interpretation accuracy of the Espiro app using pulmonologist interpretations as the gold standard. This is an observational descriptive study in which 118 spirometry results were interpreted by the Espiro app, two pulmonologists, two primary care physicians, and two residents of a primary care training program. We determined the interpretation accuracy of the Espiro app and the concordance of the pattern and severity interpretation between the Espiro app and each of the observers using Cohen’s kappa coefficient (k). We obtained a sensitivity and specificity for the Espiro app of 97.5% (95% confidence interval (CI): 86.8–99.9%) and 94.9% (95%CI: 87.4–98.6%) with pulmonologist 1 and 100% (95%CI: 91.6–100%) and 98.7% (95%CI: 92.9–99.9%) with pulmonologist 2. The concordance for the pattern interpretation was greater than k 0.907, representing almost perfect agreement. The concordance of the severity interpretation was greater than k 0.807, representing substantial to almost perfect agreement. We concluded that the Espiro app is a valid tool for spirometry interpretation.
- Open Access
- 26 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7315
Echocardiography and Electrocardiography in Detecting Atrial Cardiomyopathy: A Promising Path to Predicting Cardioembolic Strokes and Atrial Fibrillation
(1) Background: Atrial cardiomyopathy constitutes an intrinsically prothrombotic atrial substrate that may promote atrial fibrillation and thromboembolic events, especially stroke, independently of the arrhythmia. Atrial reservoir strain is the echocardiography marker with the most robust evidence supporting its prognostic utility. The main aim of this study is to identify atrial cardiomyopathy by investigating the association between left atrial dysfunction in echocardiography and P-wave abnormalities in the surface electrocardiogram. (2) Methods: This is a community-based, multicenter, prospective cohort study. A randomized sample of 100 patients at a high risk of developing atrial fibrillation were evaluated using diverse echocardiography imaging techniques, and a standard electrocardiogram. (3) Results: Significant left atrial dysfunction, expressed by a left atrial reservoir strain < 26%, showed a relationship with the dilation of the left atrium (p < 0.001), the left atrial ejection fraction < 50% (p < 0.001), the presence of advanced interatrial block (p = 0.032), P-wave voltage in lead I < 0.1 mV (p = 0.008), and MVP ECG score (p = 0.036). (4) Conclusions: A significant relationship was observed between left atrial dysfunction and the presence of left atrial enlargement and other electrocardiography markers; all of them are non-invasive biomarkers of atrial cardiomyopathy.
- 26 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7315
Open AccessEchocardiography and Electrocardiography in Detecting Atrial Cardiomyopathy: A Promising Path to Predicting Cardioembolic Strokes and Atrial Fibrillation
(1) Background: Atrial cardiomyopathy constitutes an intrinsically prothrombotic atrial substrate that may promote atrial fibrillation and thromboembolic events, especially stroke, independently of the arrhythmia. Atrial reservoir strain is the echocardiography marker with the most robust evidence supporting its prognostic utility. The main aim of this study is to identify atrial cardiomyopathy by investigating the association between left atrial dysfunction in echocardiography and P-wave abnormalities in the surface electrocardiogram. (2) Methods: This is a community-based, multicenter, prospective cohort study. A randomized sample of 100 patients at a high risk of developing atrial fibrillation were evaluated using diverse echocardiography imaging techniques, and a standard electrocardiogram. (3) Results: Significant left atrial dysfunction, expressed by a left atrial reservoir strain < 26%, showed a relationship with the dilation of the left atrium (p < 0.001), the left atrial ejection fraction < 50% (p < 0.001), the presence of advanced interatrial block (p = 0.032), P-wave voltage in lead I < 0.1 mV (p = 0.008), and MVP ECG score (p = 0.036). (4) Conclusions: A significant relationship was observed between left atrial dysfunction and the presence of left atrial enlargement and other electrocardiography markers; all of them are non-invasive biomarkers of atrial cardiomyopathy.
- Open Access
- 20 January 2023
- Published by Elsevier in Vaccine: X
- Vol. 13, 100264
Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017–2018
- 20 January 2023
- Published by Elsevier in Vaccine: X
- Vol. 13, 100264
Open AccessEvaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017–2018
- Open Access
- 23 April 2022
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 158 (6) , 251-259
Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain
- 23 April 2022
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 158 (6) , 251-259
Open AccessSusceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain
- 1 March 2022
- Published by Elsevier in Medicina Clinica
- Vol. 158 (6) , 251-259
Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain
- 1 March 2022
- Published by Elsevier in Medicina Clinica
- Vol. 158 (6) , 251-259
Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain
- Open Access
- 10 February 2022
- Published by Elsevier in Atencion Primaria
- Vol. 54 (7) , 102308
Indicadores pronósticos de la COVID-19 en atención primaria
- 10 February 2022
- Published by Elsevier in Atencion Primaria
- Vol. 54 (7) , 102308
Open AccessIndicadores pronósticos de la COVID-19 en atención primaria